Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Change in Accured Expenses (2022 - 2025)

BioXcel Therapeutics has reported Change in Accured Expenses over the past 4 years, most recently at $8.0 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $8.0 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $7.0 million (up 1047.42% YoY), and the annual figure for FY2025 was $7.0 million, up 1047.42%.
  • Change in Accured Expenses for Q4 2025 was $8.0 million at BioXcel Therapeutics, up from -$1.0 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for BTAI hit a ceiling of $8.0 million in Q4 2025 and a floor of -$5.5 million in Q2 2024.
  • Median Change in Accured Expenses over the past 4 years was -$79000.0 (2024), compared with a mean of $454800.0.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 304.53% in 2024 and later crashed 1215.19% in 2025.
  • BioXcel Therapeutics' Change in Accured Expenses stood at $908000.0 in 2022, then tumbled by 581.5% to -$4.4 million in 2023, then skyrocketed by 98.19% to -$79000.0 in 2024, then soared by 10241.77% to $8.0 million in 2025.
  • The last three reported values for Change in Accured Expenses were $8.0 million (Q4 2025), -$1.0 million (Q3 2025), and $2.3 million (Q2 2025) per Business Quant data.